Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profiling of U87 and U373 after 72 hours treatment of 1U/ml pegylated arginase I BCT-100.

ABSTRACT: In this study the effect of pegylated arginasse I on global gene expression in U87 and U373 were examined. Both cells were cultured in complete medium with PBS control or 1U/ml pegylated arginase I (BCT-100) for 72 hours. Comparative transcriptome analysis of both cell lines in PBS control versus BCT-100 treatment were performed.

ORGANISM(S): Homo sapiens

PROVIDER: GSE233759 | GEO | 2025/05/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcriptional profiling of U87 and U373 after 72 hours treatment of 1U/ml pegylated arginase I BCT-100.

Project description:Transcriptional profiling of U87 and U373 after 72 hours treatment of 1U/ml pegylated arginase I BCT-100.

| PRJNA977709 | ENA

Expression data from U373 cell lines

Project description:Intracellular progesterone receptor (PR) presents two main isoforms: PR-A and PR-B with different function and regulation. Both isoforms have been identified in astrocytomas, the most common and aggressive primary brain tumors in humans. To investigate the role of PR activity in the regulation of gene expression pattern of U373 cells, we evaluated by microarray analysis the profile of genes regulated by progesterone (10 nM), by a progesterone receptor antagonist (RU486, 10 M-BM-5M) or by both steroids. The human astrocytoma cell line U373 was treated with progesterone; the antagonist, RU-486 or a combination of both drugs.Subsecuently, total RNA was extracted and hybridised on Affymetrix Human Gene 1.0 STs.

2014-09-01 | E-GEOD-59262 | biostudies-arrayexpress

Expression data from U373 cell lines

2014-09-01 | GSE59262 | GEO

Arginine dependency is a therapeutically exploitable vulnerability in chronic myeloid leukaemic stem cells

Project description:We tested the effect of arginine depleting enzyme BCT-100 (24 hours) on primary normal and CML cells (100ng/mL for primary) as well as the wildtype or ASS1 knock-out K562 cell lines (1000ng/mL for cell lines) Cells were cultured in Plasmax Primary groups were Normal, Normal+bct, CML, CML+BCT Cell line groups were WT, WT+bct, ASS1KO, ASS1KO+BCT

2023-07-25 | GSE226887 | GEO

Transcription profiling of human PEGylated interferon-a2b treatment of one sensitive and two resistant osteosarcoma xenografts established in nude mice

Project description:Gene expression changes as a response to PEGylated interferon-a2b treatment of one sensitive and two resistant osteosarcoma xenografts established in nude mice

2010-04-12 | E-TABM-707 | biostudies-arrayexpress

Pegylated arginase I: a potential therapeutic approach in T-ALL.

Project description:Adult patients with acute lymphoblastic T cell leukemia (T-ALL) have a very poor prognosis and few effective therapeutic options. Therefore, novel therapies that increase the efficacy of the treatments and that prolong T-ALL patient survival are needed. Malignant T cells require high concentrations of nutrients to sustain their increased rate of proliferation. In this study, we determined whether L-Arginine depletion by the pegylated form of the L-Arginine-metabolizing enzyme arginase I (peg-Arg I) impairs the proliferation of malignant T cells. Our results show that peg-Arg I depleted L-Arginine levels in vitro and in vivo. In addition, treatment of malignant T-cell lines with peg-Arg I significantly impaired their proliferation, which correlated with a decreased progression into the cell cycle, followed by the induction of apoptosis. Furthermore, peg-Arg I impaired the expression of cyclin D3, a fundamental protein in T-ALL proliferation, through a global arrest in protein synthesis. Injection of peg-Arg I plus chemotherapy agent Cytarabine prolonged survival in mice bearing T-ALL tumors. This antitumoral effect correlated with an inhibition of T-ALL proliferation in vivo, a decreased expression of cyclin D3, and T-ALL apoptosis. The results suggest the potential benefit of L-Arginine depletion by peg-Arg I in the treatment of T-cell malignancies.

| S-EPMC2892956 | biostudies-literature

Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-beta-1a Compared to Non-PEGylated IFN-beta-1a

Project description:Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-beta-1a Compared to Non-PEGylated IFN-beta-1a

| PRJNA930700 | ENA

Systemic Administration of Pegylated Arginase-1 Attenuates the Progression of Diabetic Retinopathy.

Project description:Diabetic retinopathy (DR) is a serious complication of diabetes that results from sustained hyperglycemia, hyperlipidemia, and oxidative stress. Under these conditions, inducible nitric oxide synthase (iNOS) expression is upregulated in the macrophages (MΦ) and microglia, resulting in increased production of reactive oxygen species (ROS) and inflammatory cytokines, which contribute to disease progression. Arginase 1 (Arg1) is a ureohydrolase that competes with iNOS for their common substrate, L-arginine. We hypothesized that the administration of a stable form of Arg1 would deplete L-arginine's availability for iNOS, thus decreasing inflammation and oxidative stress in the retina. Using an obese Type 2 diabetic (T2DM) db/db mouse, this study characterized DR in this model and determined if systemic treatment with pegylated Arg1 (PEG-Arg1) altered the progression of DR. PEG-Arg1 treatment of db/db mice thrice weekly for two weeks improved visual function compared with untreated db/db controls. Retinal expression of inflammatory factors (iNOS, IL-1β, TNF-α, IL-6) was significantly increased in the untreated db/db mice compared with the lean littermate controls. The increased retinal inflammatory and oxidative stress markers in db/db mice were suppressed with PEG-Arg1 treatment. Additionally, PEG-Arg1 treatment restored the blood-retinal barrier (BRB) function, as evidenced by the decreased tissue albumin extravasation and an improved endothelial ZO-1 tight junction integrity compared with untreated db/db mice.

| S-EPMC9497170 | biostudies-literature

Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia.

Project description:New treatments for adults with acute lymphoblastic T-cell leukemia (T-ALL) are urgently needed, as the current rate of overall remission in these patients is only about 40 percent. We recently showed the potential therapeutic benefit of the pegylated-human-arginase I (peg-Arg I) in T-ALL. However, the mechanisms by which peg-Arg I induces an anti-T-ALL effect remained unknown. Our results show the induction of T-ALL cell apoptosis by peg-Arg I, which associated with a global arrest in protein synthesis and with the phosphorylation of the eukaryotic-translation-initiation factor 2 alpha (eIF2?). Inhibition of eIF2? phosphorylation in T-ALL cells prevented the apoptosis induced by peg-Arg I, whereas the expression of a phosphomimetic eIF2? form increased the sensibility of T-ALL cells to peg-Arg I. Phosphorylation of eIF2? by peg-Arg I was mediated through kinases PERK and GCN2 and down-regulation of phosphatase GADD34. GCN2 and decreased GADD34 promoted T-ALL cell apoptosis after treatment with peg-Arg I, whereas PERK had an unexpected anti-apoptotic role. Additional results showed that phospho-eIF2? signaling further increased the anti-leukemic effects induced by peg-Arg I in T-ALL-bearing mice. These results suggest the central role of phospho-eIF2? in the anti-T-ALL effects induced by peg-Arg I and support its study as a therapeutic target.

| S-EPMC3594435 | biostudies-literature

B cells enhanced the anti-U251/U373 activity of EphA2-CAR T cells

Project description:B cells enhanced the anti-U251/U373 activity of EphA2-CAR T cells

| PRJNA915028 | ENA